Advantages and pitfalls of combining intravenous antithrombin with nebulized heparin and tissue plasminogen activator in acute respiratory distress syndrome.

Abstract

BACKGROUND:

Pulmonary coagulopathy has become an important therapeutic target in adult respiratory distress syndrome (ARDS). We hypothesized that combining intravenous recombinant human antithrombin (rhAT), nebulized heparin, and nebulized tissue plasminogen activator (TPA) more effectively improves pulmonary gas exchange compared with a single rhAT infusion, while maintaining the anti-inflammatory properties of rhAT in ARDS. Therefore, the present prospective, randomized experiment was conducted using an established ovine model.

METHODS:

Following burn and smoke inhalation injury (40% of total body surface area, third-degree flame burn, and 4 × 12 breaths of cold cotton smoke), 18 chronically instrumented sheep were randomly assigned to receive intravenous saline plus saline nebulization (control), intravenous rhAT (6 IU/kg/h) started 1 hour after injury plus saline nebulization (AT i.v.) or intravenous rhAT combined with nebulized heparin (10,000 IU every 4 hours, started 2 hours after injury), and nebulized TPA (2 mg every 4 hours, started 4 hours after injury) (triple therapy, n = 6 each). All animals were mechanically ventilated and fluid resuscitated according to standard protocols during the 48-hour study period.

RESULTS:

Both treatment approaches attenuated ARDS compared with control animals. Notably, triple therapy was associated with an improved PaO2/FiO2 ratio (p = 0.007), attenuated pulmonary obstruction (p = 0.02) and shunting (p = 0.025), as well as reduced ventilatory pressures (p < 0.05 each) versus AT i.v. at 48 hours. However, the anti-inflammatory effects of sole AT i.v., namely, the inhibition of neutrophil activation (neutrophil count in the lymph and pulmonary polymorphonuclear cells, p < 0.05 vs. control each), pulmonary transvascular fluid flux (lymph flow, p = 0.004 vs. control), and systemic vascular leakage (cumulative net fluid balance, p < 0.001 vs. control), were abolished in the triple therapy group.

CONCLUSION:

Combining intravenous rhAT with nebulized heparin and nebulized TPA more effectively restores pulmonary gas exchange, but the anti-inflammatory effects of sole rhAT are abolished with the triple therapy. Interferences between the different anticoagulants may represent a potential explanation for these findings.

• Authors: Sebastian Rehberg, Yusuke Yamamoto, Linda E Sousse, Collette Jonkam, Robert A Cox, Donald S Prough, Perenlei Enkhbaatar
• Journal: The journal of trauma and acute care surgery (J Trauma Acute Care Surg) Vol. 76 Issue 1 Pg. 126-33 (Jan 2014) ISSN: 2163-0763 [Electronic] United States
• PMID: 24368367 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Antithrombins
• Recombinant Proteins
• Heparin
• Tissue Plasminogen Activator

Topics

• Administration, Inhalation
• Administration, Intravenous
• Animals
• Antithrombins (administration & dosage, therapeutic use)
• Disease Models, Animal
• Drug Therapy, Combination
• Female
• Heparin (administration & dosage, therapeutic use)
• Nebulizers and Vaporizers
• Pulmonary Gas Exchange (drug effects)
• Recombinant Proteins (administration & dosage, therapeutic use)
• Respiration, Artificial
• Respiratory Distress Syndrome (drug therapy)
• Sheep
• Tissue Plasminogen Activator (administration & dosage, therapeutic use)